Corbus’ Nectin-4 ADC Shows Promise in Western Study, Challenging Pfizer’s Padcev
Corbus presented data from its Western Phase 1 study of CRB-701, a Nectin-4 targeting antibody-drug conjugate, at ASCO-GU 2025147.
The Western study results were largely consistent with earlier data from a Chinese trial, showing a 27% response rate in 26 evaluable patients1.
CRB-701 demonstrated efficacy in urothelial cancer, cervical cancer, and notably in head and neck squamous cell carcinoma (HNSCC)7.
The safety profile of CRB-701 appears favorable, with lower rates of peripheral neuropathy and skin toxicity compared to Pfizer's Padcev79.
Corbus is optimizing dosing at 2.7 mg/kg and 3.6 mg/kg every 3 weeks, which may offer a more convenient regimen than Padcev710.
The company believes CRB-701 has potential advantages over Padcev, including a longer half-life and lower drug-antibody ratio1.
Despite promising data, Corbus' stock experienced some volatility, with a 10% drop in premarket trading following the announcement1.
The development of CRB-701 represents Corbus' pivot to oncology after previous setbacks in other therapeutic areas3.
Sources:
1. https://www.fiercebiotech.com/biotech/corbus-posts-first-us-data-challenger-pfizers-adc-padcev
3. https://www.oncologypipeline.com/apexonco/asco-gu-corbus-throws-its-hat-nectin-4-ring
4. https://www.corbuspharma.com/press-releases/detail/434/corbus-pharmaceuticals-announces-clinical-data-for-crb-701
7. https://www.corbuspharma.com/press-releases/detail/435/crb-701-sys6002-a-next-generation-nectin-4-targeting-adc
9. https://www.globenewswire.com/news-release/2025/02/14/3026580/0/en/CRB-701-SYS6002-A-Next-Generation-Nectin-4-Targeting-ADC-Demonstrates-Encouraging-Safety-and-Broader-Efficacy-in-Phase-1-Study-in-the-US-and-UK-Presented-at-ASCO-GU-2025.html
10. https://endpts.com/ascogu-corbus-shares-dip-on-mixed-phase-1-solid-tumor-data-for-nectin-4-adc/